

CURRICULUM VITAE

ALEXANDER BYSTRITSKY, M.D., Ph.D.

PERSONAL INFORMATION

Brainsonix Corp./CalNeuro/WNT/ ABCAnxiety
10850 Wilshire Blvd, Suite 1260
Los Angeles, CA 90024

UCLA Neuropsychiatric Institute and Hospital
300 UCLA Medical Plaza, Suite 2340, Los Angeles, CA 90024
Business Tel.: (310) 206-5177 / (310) 206-5133

Born: January 18, 1954; Leningrad, U.S.S.R.
Citizen of U.S.A.

EDUCATION

1971-1977

Pavlov Medical University, St. Petersburg, Russia
M.D.

1977-1979

Pavlov Medical University, St. Petersburg, Russia
Ph.D. (equivalent) – Psychopharmacology

1981-1985

New York University-Bellevue Medical Center, New York, NY
Resident in Psychiatry (Chief Resident of Anxiety Disorders
Program as PGY-4)

1985-1987

University of California, Los Angeles, Los Angeles, CA
Robert Wood Johnson Clinical Scholar

2003-2006

Ph.D. degree in Clinical Psychiatry and Neuropharmacology,
St. Petersburg Medical University,

LICENSURE

State of California # A04132
State of New York # 159550
(inactive)

BOARD CERTIFICATION

American Board of Psychiatry and Neurology # 30209

PROFESSIONAL EXPERIENCE

Present positions:

- CEO, Brainsonix Corporation, Los Angeles, California
- Co-Founder/Executive Director, Tiny Blue Dot Foundation,
Santa Monica, CA
- Co-Founder and President, Institute for Advanced Consciousness Studies,
Santa Monica, CA
- President, ABCanxiety. Inc, Los Angeles, CA
- President, Pacific Institute of Medical Research
- Principal Investigator, CalNeuro, Inc., Los Angeles, CA
- Principal Consultant, WestSide NeuroTherapeutics
- Chief Medical Officer, Consumer Brands, Inc
- Co-Founder and Chief Scientific Officer, Synaptec Research
Santa Monica, California
- Professor Emeritus of Psychiatry and Biobehavioral Sciences,
UCLA School of Medicine
- Director Emeritus, Anxiety Disorder Program and Targeted Brain
Stimulation Program, Semel Institute of Neuroscience and Human
Behavior, UCLA, Los Angeles, CA

Curriculum Vitae

Alexander Bystritsky, M.D., Ph.D.

- 1977-1979 Ph.D. Candidate
Pavlov Medical University, St. Petersburg, Russia
Institute of Experimental Medicine
- 1980-1981 Assistant Research Scientist
New York University Medical Center
- 1981-1985 Resident in Psychiatry (Chief Resident of Anxiety Disorders
Program as PGY-4)
New York University-Bellevue Medical Center, New York, NY
- 1985-1987 Robert Wood Johnson Clinical Scholar
University of California, Los Angeles, Los Angeles, CA
- 1987- Director of Anxiety Disorders Program
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 1987-2009 Director of Outpatient Psychopharmacology
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 1990- Attending Physician, Neuropsychiatric Hospital
University of California, Los Angeles, Los Angeles, CA
- 1991-2009 Director, Partial Hospitalization Program for Treatment Resistant
Anxiety Disorder, Neuropsychiatric Hospital
University of California, Los Angeles, Los Angeles, CA
- 1997 - 2000 Associate Director, Clinical Psychopharmacology Research Center
Neuropsychiatric Institute and Hospital
University of California, Los Angeles, Los Angeles, CA
- 2007 - 2011 Visiting Professor at Full Professor Level, Neuroscience and
Radiology, Brigham and Women's Hospital, Harvard School of
Medicine, Boston, Massachusetts
- 2003- President and CEO, Brainsonix Corporation, Sherman Oaks, CA
- 2017- Executive Director, Tiny Blue Dot Foundation, Santa Monica, CA

Curriculum Vitae

Alexander Bystritsky, M.D., Ph.D.

- 2018- President, ABCanxiety, a Specialized Clinical Practice
Los Angeles, CA
- 2018- Principal Investigator, CalNeuro, Inc, a Clinical Trial Site
Los Angeles, CA
- 2018- Medical Director, West Side Neurotherapeutics, Inc,
Los Angeles CA

- 2019 - President, Institute for Advanced Consciousness Studies

- 2019 - Chief Scientific Officer of Synaptec Research

PROFESSIONAL ACTIVITIES**Memberships**

American Psychiatric Association
 Southern California Psychiatric Society
 Anxiety Disorders Association of America
 Russian-American Medical Society
 Western Coast College of Biological Psychiatry
 California Alliance for Mentally Ill
 OCD Foundation
 College Internationale NeuroPsychopharmacology
 American Society of Pharmacology and Therapeutics
 American Society of Clinical Psychopharmacology
 Bellevue Psychiatric Society

Committee/Community/Teaching Service

1986-2007 Volunteer Psychiatric Consultant for The Russian-American Society and Jewish Community Services of Los Angeles
 1987-2018 Member, UCLA Pharmacy and Therapeutics Committee
 1987- PGY 2-4 Residents' Supervisor
 1987- Lecturer for UCLA Clinical Pharmacology Course
 1994- Expert Treatment Panel of Anxiety Disorders Association of America
 1995-2011 Chair, Committee on Clinical Trials, American Society for Clinical Psychopharmacology
 1995-1998 Chair, Committee on International Affairs, Southern California Psychiatric Society
 1997-2007 Member, Scientific Advisory Board, OCD Foundation, Western Region
 1997-2011 Treatment and Assessment Consultant for Anxiety Disorders Rand Corporation, Santa Monica

Editorial Service

1987- Reviewer for Archives of General Psychiatry
 1989- Reviewer for Journal of Anxiety Disorders
 1990- Reviewer for American Journal of Psychiatry
 1993- Reviewer for Journal of Nervous Mental Disorder
 1993- Reviewer for Depression and Anxiety
 1994- Reviewer for Journal of Geriatric Psychiatry
 2003- Invited Guest Editor for Focus Publications
 2011-2016 Associate Editor, Brain and Behavior
 2014- Editor, American Society Clinical Psychopharmacology Website
 2014- Chief Editor, Anxiety.org

HONORS AND SPECIAL AWARDS

1975	Best Student Research Paper Leningrad.
1976	Gold Medal for Best Student Research Paper in U.S.S.R. among Medical, Physical and Mathematical Sciences
1977	Maria Petrova Award - The Most Outstanding Young Scientist Paper in the fields of Psychiatry and Neurology in the U.S.S.R.
1985	Robert Wood Johnson Clinical Scholar
1994	Bristol Myers Distinguished Faculty
1994	Janssen Clinical Scholar
1994	Special Recognition Service Award, SCPA
1995-	Who's Who in the United States, #16531
1996	Physician Recognition Award, California Medical Association
1996	Best Doctors in Los Angeles, LA Magazine Listing
1998-	Best Doctors in America
1999-	Who is Who in the World
2000-	America's Top Doctors
2001-	Distinguished Life Fellow of American Psychiatric Association
2005-	Man of the Year Listings
2005	OC Foundation Research Award
2009	NARSAD Distinguished Investigator Award
2016	Life Fellow American Society of Clinical Psychopharmacology
2016	Wired Magazine, Best Things in The World, 2016

PUBLICATION/BILIOGRAPHY**RESEARCH PAPERS (peer reviewed)**

1. Rabey JM, Passeltiner P, **Bystritsky A**, Engel J, Goldstein M. The regulation of striatal dopa synthesis by alpha-2 adrenoreceptors, Brain Res, 230:422-426, 1981.
2. Goldstein M, Engel J, **Bystritsky A**, Mino S. Therapeutic potentials of centrally acting dopamine and alpha-2 receptor agonists, J Neural Transm, 18:257-265, 1983.
3. Fogelson DL, **Bystritsky A**, Sussman N. Interrelationships between major depression and the anxiety disorders: Clinical relevance, Psychiatric Annals, 18:31 158-167, 1988.
4. Fogelson D, **Bystritsky A**, Katz R, DeVeaugh -Geiss J, Landau P. Obsessive-compulsive disorder treatment response to clomipramine hydrochloride and influence of affective disturbance, Biol Psychiatry, (Supplement) 25:184a-193a, 1989.
5. Pasnau RO, **Bystritsky A**. Overview of anxiety disorders. Bull Menninger Clin, 54(2):157-169, 1990.
6. Pasnau RO, **Bystritsky A**. The importance of treating anxiety in elderly ill patients, Psychiatric Medicine, 8(3):163-173, 1990.
7. **Bystritsky A**, Ware JE, Linn LS. Development of a multidimensional scale of anxiety, Journal of Anxiety Disorders, 4:99-115, 1990.
8. Levine S, Anderson D, **Bystritsky A**, Baron D. A report of eight HIV-seropositive patients with major depression responding to fluoxetine, J Acquir Immune Defic Syndr, 3:1074-1077, 1990.
9. **Bystritsky A**, Pasnau RO. Initial reaction and response to antidepressants, Am J Psychiatry, 147:11:1575, 1990.
10. **Bystritsky A**, Ackerman DL, Pasnau RO. Low dose desipramine treatment of cocaine related panic attacks, J Nerv Ment Dis, 179:755-758, 1991.
11. **Bystritsky A**, Pasnau RO. Switching from alprazolam to buspirone, J Clin Psychopharmacol, 11:3:219-220, 1991.
12. Fogelson DL, **Bystritsky A**. Imipramine in the treatment of obsessive compulsive disorder with and without depression, Ann Clin Psychiatry, 3:3:1230-1237, 1991.
13. Levine S, **Bystritsky A**, Barron D, Jones L. Group psychotherapy for HIV-seropositive patients with major depression, Am J Psychother, XLV:2:112-116, 1991.

14. Fogelson DL, **Bystritsky A**, Pasnau RO. Bupropion in the treatment of bipolar disorders: The same old story, J Clin Psychiatry, 53:443-446, 1992.
15. Davis KL and the Tacrine Collaborative Study Group (**Bystritsky** named as member). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease, N Engl J Med, 327(18):1253-1259, 1992.
16. **Bystritsky A**, Shapiro D. Continuous physiological and subjective reports in panic patients: A preliminary methodological report, Biol Psychiatry, 32:766-777, 1992.
17. **Bystritsky A**, Fogelson DL, Doctor R, Yager J. Symptom differences among patients in clinics with differing treatment orientations, Am J Psychother, 2:2:164-170, 1993.
18. **Bystritsky A**, Stoessel P, Yager J. Psychometric discrimination between anxiety and depression, J Nerv Ment Dis, 181:4:265-267, 1993.
19. Katz RJ, Landau PS, Lott M, **Bystritsky A**, Diamond B, Hoehn-Saric R, Rosenthal M, Schweizer E, Weise C. Serotonergic (5-HT₂) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorders: 5-HT₂, Biol Psychiatry, 34:41-44, 1993.
20. Mendels J, Johnston R, Mattes J, Riesenber R (An Expert's Group, **Bystritsky** named as member). Efficacy and safety of b.i.d. doses of venlafaxine in a dose- response study, Psychopharmacol Bull, 29:169-174, 1993.
21. Sherbourne CD, Wells KB, Judd LL, with Panic Disorder Outcome Study Team, (An Expert's Group, **Bystritsky** named as member). Rand Publication, 1994.
22. Shear MK, Maser J, (An Expert's Group, **Bystritsky** named as member). Standardized assessment for panic disorder research, Arch Gen Psychiatry, 51:346-364, 1994.
23. Ackerman DL, Greenland S, **Bystritsky A**, Morgenstern H, Katz RJ. Predicators of treatment response in obsessive compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine, J Clin Psychopharmacol, 14:4:247-254, 1994.
24. **Bystritsky A**, Waikar SV. Inert placebo versus active medication: Patient blindability in clinical pharmacological trials, J Nerv Mental Dis, 182:9:485-487, 1994.
25. Targ EF, Karasic DH, Diefenbach PN, Anderson DA, **Bystritsky A**, Fawzy FI. Structured group therapy and fluoxetine to treat depression in HIV-positive persons, Psychosomatics, 35:(2):132-137, 1994.
26. Waikar SV, **Bystritsky A**, Craske MG, Murphy KJ. Etiological beliefs and treatment seeking behavior in anxiety-disordered patients, Anxiety, 1:134-137, 1995.

27. **Bystritsky A**, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T. Double-blind pilot trial of desipramine vs. fluoxetine in panic patients, J of Anxiety Disorders, 1:287-290, 1995.
28. Stoessel PW, **Bystritsky A**, Pasnau RO. Distinguishing anxiety disorders patients from medical patients in the outpatient medical setting, Family Practice, 12:448-451, 1995.
29. **Bystritsky A**, Craske M, Maidenberg E, Vapnik T, Shapiro D. Ambulatory monitoring of panic patients during regular activity: A preliminary report. Biol Psychiatry, 38:10:684-689, 1995.
30. Craske MG, Maidenberg E, **Bystritsky A**. Brief cognitive-behavioral versus nondirective therapy for panic disorder, J Behav Ther Exp Psychiatry, 26:113-120, 1995.
31. **Bystritsky A**, Waikar S, Vapnik T. The four-dimensional anxiety and depression scale, Anxiety, 2:47-50, 1995.
32. Small GW, Hamilton SH, **Bystritsky A**, Meyers BS, Nemeroff CB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression, Int Psychogeriatr, 7:41-53, 1995.
33. **Bystritsky A**, Munford PR, Rosen RM, Martin KM, Vapnik T, Gorbis EE, Wolson RC. A preliminary study of partial hospital management of severe obsessive-compulsive disorder, Psychiatr Serv, 47:170-174, 1996.
34. Ackerman DL, Greenland S, **Bystritsky A**. Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy, Psychopharmacol Bull, 32:157-165, 1996.
35. Small GW, Schneider LS, Holman SL, **Bystritsky A**. Site variability in multicenter geriatric desipramine trial, International Journal of Geriatric Psychiatry, 11:1-7, 1996.
36. Saxena S, Wang D, **Bystritsky A**, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder, J Clin Psychiatry, 57:7:303-306, 1996.
37. Maidenberg E, Chen E, Craske MG, Bohn PB, **Bystritsky A**. Specificity of attention bias in panic disorder and social phobia. Journal of Anxiety Disorders, 10:529-541, 1996.
38. Small G, Birkett, M, Meyers BS, Koran LM, **Bystritsky A**, Nemeroff CB. Impact of physical illness on quality of life and antidepressant response in geriatric major depression, J Am Geriatr Soc, 44:10:1220-1225, 1996.
39. **Bystritsky A**, Strusser B. Treatment of obsessive-compulsive cutting behavior with naltrexone, J Clin Psychiatry, 57:423-424, 1996.

40. Ackerman DL, Greenland S, **Bystritsky A**, Katz RJ. Relationship between early side effects and therapeutic effects of clomopramine therapy in obsessive-compulsive disorder, J Clin Psychopharmacol, 16:324-328, 1996.
41. **Bystritsky A**, Vapnik T. Treatment of dysmorphophobia using videotape exposure, Depression and Anxiety, 5:1:39-41, 1997.
42. March JS et al., (**Bystritsky**, member of panel). The expert consensus panel report for obsessive-compulsive disorder, J Clin Psychiatry, 58(Suppl 4), 1997.
43. Schneider LS, Small GW, Hamilton SH, **Bystritsky A**, Nemeroff CB, Meyers BS. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial: Fluoxetine collaborative study group, American Journal of Geriatric Psychiatry, 5(2):97-106, 1997.
44. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Characteristics of fluoxetine vs. placebo responders in a randomized trial of geriatric depression, Psychopharmacol Bull, 33:4:707-714, 1998.
45. Roy-Byrne P, Stein M, **Bystritsky A**, Katon W. Pharmacotherapy of panic disorder: Proposed guidelines for the family physician, J Am Board of Fam Pract, 11: 282-90, 1998.
46. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG abnormalities in non-medicated panic patients, J Nerv Ment Dis, 187:2:113-114, 1999.
47. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Psychiatr Serv, 50:3:412-413, 1999.
48. Kronig MH, Apter J, Asnis G, **Bystritsky A**, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenbergr R, Robinson D, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder, J Clin Psychopharmacol, 19(2):172, 1999.
49. Foa EB, Davidson JRT, Frances A, Expert Group (**Bystritsky**, member). Expert consensus guideline for the treatment of post traumatic stress disorder, J Clin Psychiatry, Supplement 16, 1999.
50. Roy-Byrne PP, Stein MB, Russo J, Mercier E, Thomas R, McQuaid J, Katon W, Craske MG, **Bystritsky A**, Sherbourne C. Panic disorder in the primary care setting: Comorbidity, disability, service utilization and treatment, J Clin Psychiatry, 60:492-499, 1999.
51. Stein MB, Roy-Byrne PP, McQuaid JR, Laffaye C, Russo J, McCahill ME, Katon W, Craske MG, **Bystritsky A**, Sherbourne CD. Development of a brief diagnostic screen in panic disorder in primary care, Psychosom Med, 61:359-364, 1999.

52. Ackerman DL, Greenland S, **Bystritsky A**. Side effects as predictors of drug response in obsessive-compulsive disorder, J Clin Psychopharmacol, 19(5):459-65, 1999.
53. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Depress Anxiety, 10(3):137-9, 1999.
54. **Bystritsky A**, Vapnik T, Maidment K, Pynoos RS, Steinberg AM. Acute responses of anxiety disorder patients after a natural disaster, Depress Anxiety, 11(1):43 -4, 2000.
55. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity of panic patients during a CO₂ inhalation procedure, Depress Anxiety, 11(1):15-26, 2000.
56. **Bystritsky A**, Craske M, Maidenberg E, Shapiro D. Autonomic reactivity in panic patients during structured psychophysiological assessment, Depress Anxiety, 2(2):102-8, 2000.
57. Ackerman DL, Greenland S, **Bystritsky A**, Small GW. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression, J Clin Psychopharmacol, 20(6):658-65, 2000.
58. Saxena S, Winograd A, Dunkin JJ, Maidment K, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder, J Clin Psychiatry, 62(1):67-72, 2001.
59. **Bystritsky A**, Liberman RP, Hwang S, Wallace CJ, Vapnik T, Maidment K, Saxena S. Social functioning and quality of life comparisons between obsessive-compulsive and schizophrenic disorders, Depress Anxiety, 14(4):214-8, 2001.
60. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. Functional MRI changes during panic anticipation and imagery exposure, Neuroreport, Dec 21;12(18):3953-7, 2001.
61. Klein DF, Thase M, Endicott J, Adler L, Glick I, Kalali A, Levanter S, Mattes J, Ross P, **Bystritsky A**. Improving clinical trials: American society of clinical psychopharmacology recommendations, Arch Gen Psychiatry, Mar;59(3):272-8, 2002.
62. Craske MC, Lang AJ, Rowe M, DeCola JP, Simmons J, Mann C, Yan-Go F, **Bystritsky A**. Pre-sleep attributions about arousal during sleep: Nocturnal panic, J Abnorm Psychol, Feb;111(1):53-62, 2002.
63. Saxena S, Maidment KM, Rosen R, Vapnik T, Tarlow G, **Bystritsky A**. Obsessive-compulsive hoarding: symptom severity and response to multi-modal treatment, J Clin Psychiatry, Jan;63(1):21-7, 2002.

64. Hazlett-Stevens H, Craske MG, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A**. Predictors of willingness to consider medication and psychosocial treatment for panic disorder in primary care patients, Gen Hosp Psychiatry, Sep-Oct;24(5):316-21, 2002.
65. Craske MG, Roy-Byrne P, Stein MB, Donald-Sherbourne C, **Bystritsky A**, Katon W, Sullivan G. Treating panic disorder in primary care: a collaborative care intervention, Gen Hosp Psychiatry, May-Jun;24(3):148-55, 2002.
66. Craske MG, Lang AJ, Mystkowski JL, Zucker BG, **Bystritsky A**, Yan-Go F. Does nocturnal panic represent a more severe form of panic disorder?, J Nerv Ment Dis, Sep;190(9):611-8, 2002.
67. **Bystritsky A**. Anxiety Disorders: Alternative Treatment Strategies, Primary Psychiatry, Jul; 202:8-10, 2002.
68. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. Moving treatment research from clinical trials to the real world, Psychiatric Services, 54:327-332, 2003.
69. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Psychological Medicine, 33:1-8, 2003.
70. Means-Christensen A, Sherbourne CD, Roy-Byrne P, Craske MG, **Bystritsky A**, Stein MB. The Composite International Diagnostic Interview (CIDI-Auto): problems and remedies for diagnosing panic disorder and social phobia, International Journal of Methods in Psychiatric Research, 12:167-181, 2003.
71. **Bystritsky A**. Diagnosis and Treatment of Anxiety, Focus Publications, Vol II, 3:333-343, 2004.
72. **Bystritsky A**. Current Pharmacological Treatments for Obsessive-Compulsive Disorder, Essential Psychopharmacology, 5(4):251-272, 2004.
73. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.
74. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. Apr;65(4):565-8, 2004.
75. Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, **Bystritsky A**, Katon W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety disorders, Am J Psychiatry, Dec;161(12):2230-7, 2004.

76. **Bystritsky A.** Anxiety Disorders: Diagnosis, Dimensions, and Process, Primary Psychiatry, Nov;12(11):33-34, 2005.
77. Feusner J, Cameron M, **Bystritsky A.** Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov;12:49-55, 2005.
78. Stein MB, Pollack MH, **Bystritsky A**, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial, Psychopharmacology (Berl), Jan;177(3):280-8, 2005.
79. Bogan AM, Koran LM, Chuong HW, Vapnik T, **Bystritsky A.** Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study, J Clin Psychiatry, Jan;66(1):73-9, 2005.
80. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, **Bystritsky A**, Katon W, Golinelli D, Sherbourne CD. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder, Arch Gen Psychiatry, Mar;62(3):290-8, 2005.
81. Roy-Byrne PP, **Bystritsky A**, Russo J, Craske MG, Sherbourne CD, Stein MB. Use of herbal medicine in primary care patients with mood and anxiety disorders, Psychosomatics, Mar-Apr;46(2):117-22, 2005.
82. Wagner AW, **Bystritsky A**, Russo JE, Craske MG, Sherbourne CD, Stein MB, Roy-Byrne PP. Beliefs about psychotropic medication and psychotherapy among primary care patients with anxiety disorders, Depress Anxiety, 21(3):99-105, 2005.
83. Craske MG, Edlund MJ, Sullivan G, Roy-Byrne P, Sherbourne C, **Bystritsky A**, Stein MB. Perceived unmet need for mental health treatment and barriers to care among patients with panic disorder, Psychiatr Serv, Aug;56(8):988-94, 2005.
84. **Bystritsky A**, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.
85. **Bystritsky A.** Diagnosis and Treatment of Anxiety (in Russian), Bridging Eastern and Western Psychiatry, III(2):1-11, 2005.
86. Kobak KA, Taylor LV, **Bystritsky A**, Kohlenberg CJ, Greist JH, Tucker P, Warner G, Futterer R, Vapnik T. St John's Wort versus placebo in obsessive-compulsive disorder: results from a double-blind study, Int Clin Psychopharmacol, Nov;20(6):299-304, 2005.
87. Craske MG, Golinelli D, Stein MB, Roy-Byrne P, **Bystritsky A**, Sherbourne C. Does the addition of cognitive behavioral therapy improve panic disorder treatment outcome relative to medication alone in the primary-care setting?, Psychol Med, Nov;35(11):1645-54, 2005. Stein MB, Roy-

Byrne PP, Craske MG, **Bystritsky A**, Sullivan G, Pyne JM, Katon W, Sherbourne CD. Functional impact and health utility of anxiety disorders in primary care outpatients, Med Care, Dec;43(12):1164-70, 2005.

88. **Bystritsky A**. Anxiety Disorders: Diagnosis, Dimensions and Process, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.

89. Feusner J, Cameron M, **Bystritsky A**. Pharmacotherapy and Psychotherapy for Panic Disorder, Primary Psychiatry, Nov; 12 (11) 33-34, 2005.

90. **Bystritsky A**, Wagner AW, Russo JE, Stein MB, Sherbourne CD, Craske MG, Roy-Byrne PP. Assessment of beliefs about psychotropic medication and psychotherapy: development of a measure for patients with anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;27(5):313-8, 2005.

91. Bell S, Shipman M, **Bystritsky A**, Haifley T. Fluoxetine treatment and testosterone levels, Ann Clin Psychiatry, Jan-Mar;18(1):19-22, 2006.

92. **Bystritsky A**. Treatment-resistant anxiety disorders, Mol Psychiatry, Sep;11(9):805-14, 2006.

93. **Bystritsky A**, Zvartau EE, Neznanov NG. Differential Diagnosis of Panic Disorder (in Russian), Psychiatry and Medical Psychology, 3:16-20, 2006.

94. Craske MG, Roy-Byrne P, Stein MB, Sullivan G, Hazlett-Stevens H, **Bystritsky A**, Sherbourne C. CBT intensity and outcome for panic disorder in a primary care setting, Behav Ther, Jun;37(2):112-9, 2006.

95. Sullivan G, Craske MG, Sherbourne C, Edlund MJ, Rose RD, Golinelli D, Chavira DA, **Bystritsky A**, Stein MB, Roy-Byrne PP. Design of the Coordinated Anxiety Learning and Management (CALM) study: innovations in collaborative care for anxiety disorders, Gen Hosp Psychiatry, Sep-Oct;29(5):379-387, 2007.

96. Feusner JD, Townsend J, **Bystritsky A**, Bookheimer S. Visual Information Processing of Faces in Body Dysmorphic Disorder, Arch Gen Psychiatry. 2007 Dec;64(12):1417-25.

98. **Bystritsky A**, Kerwin L, Feusner JD. A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD). J Altern Complement Med. 2008 Mar;14(2):175-80.

99. **Bystritsky A**, Kerwin L, Feusner J. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. J Clin Psychiatry. 2008 Mar;69(3):412-7.

100. **Bystritsky A**, Kerwin L, Feusner JD, Vapnik T. A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder. Psychopharmacol Bull. 2008;41(1):46-51.

101. Campbell-Sills L, Norman SB, Craske MG, Sullivan G, Lang AJ, Chavira DA,

- Bystritsky A**, Sherbourne C, Roy-Byrne P, Stein MB. Validation of a brief measure of anxiety-related severity and impairment: the Overall Anxiety Severity and Impairment Scale (OASIS). J Affect Disord. 2009 Jan;112(1-3):92-101.
102. Powers MB, Smits JA, Whitley D, **Bystritsky A**, Telch MJ. The effect of attributional processes concerning medication taking on return of fear. J Consult Clin Psychol. 2008 Jun;76(3):478-90.
103. **Bystritsky A**, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2008 Jul;69(7):1092-8.
104. Feusner JD, Kerwin L, Saxena S, **Bystritsky A**. Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial. Psychopharmacol Bull. 2009;42(1):81-93.
105. Craske MG, Rose RD, Lang A, Welch SS, Campbell-Sills L, Sullivan G, Sherbourne C, **Bystritsky A**, Stein MB, Roy-Byrne PP. Computer-assisted delivery of cognitive behavioral therapy for anxiety disorders in primary-care settings. Depress Anxiety. 2009;26(3):235-42.
106. Roy-Byrne P, Veitengruber JP, **Bystritsky A**, Edlund MJ, Sullivan G, Craske MG, Welch SS, Rose R, Stein MB. Brief intervention for anxiety in primary care patients. J Am Board Fam Med. 2009 Mar-Apr;22(2):175-86.
107. **Bystritsky A**, Kerwin LE, Feusner JD. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder: 6-month follow-up. J Clin Psychiatry. 2009 Mar;70(3):431-2.
108. Feusner JD, Townsend J, **Bystritsky A**, McKinley M, Moller H, Bookheimer S. Regional brain volumes and symptom severity in body dysmorphic disorder. Psychiatry Res. 2009 May 15;172(2):161-7.
109. Craske MG, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**. Treatment for anxiety disorders: Efficacy to effectiveness to implementation. Behav Res Ther. 2009 Nov;47(11):931-7.
110. Chavira DA, Stein MB, Golinelli D, Sherbourne CD, Craske MG, Sullivan G, **Bystritsky A**, Roy-Byrne PP. Predictors of clinical improvement in a randomized effectiveness trial for primary care patients with panic disorder. J Nerv Ment Dis. 2009 Oct;197(10):715-21.
111. **Bystritsky A**, Kerwin L, Niv N, Natoli JL, Abrahami N, Klap R, Wells K, Young AS. Clinical and subthreshold panic disorder. Depress Anxiety. 2010 Apr;27(4):381-9.
112. Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, **Bystritsky A**, Stein MB. Functioning and disability levels in primary

care out-patients with one or more anxiety disorders. Psychol Med. 2010 Feb 11:1-10.

113. Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, **Bystritsky A**, Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8.
114. Feusner JD, **Bystritsky A**, Helleman G, Bookheimer S. Impaired identity recognition of faces with emotional expressions in body dysmorphic disorder. Psychiatry Res. 2010 May 19.
115. Saxena S, Ayers CR, Maidment KM, Vapnik T, Wetherell JL, **Bystritsky A**. Quality of life and functional impairment in compulsive hoarding. J Psychiatr Res. 2011 Apr;45(4):475-80. Epub 2010 Sep 6.
116. Rabinovich MI, Muezzinoglu MK, Strigo I, **Bystritsky A**. Dynamical principles of emotion-cognition interaction: mathematical images of mental disorders. PLoS One. 2010 Sep 21;5(9):e12547.
117. Yoo SS, **Bystritsky A**, Lee JH, Zhang Y, Fischer K, Min BK, McDannold NJ, Pascual-Leone A, Jolesz FA. Focused ultrasound modulates region-specific brain activity. Neuroimage. 2011 Feb 24
118. Stein MB, Roy-Byrne PP, Craske MG, Campbell-Sills L, Lang AJ, Golinelli D, Rose RD, **Bystritsky A**, Sullivan G, Sherbourne CD. Quality of and patient satisfaction with primary health care for anxiety disorders. J Clin Psychiatry. 2011 Feb 22.
119. Min BK, **Bystritsky A**, Jung KI, Fischer K, Zhang Y, Maeng LS, In Park S, Chung YA, Jolesz FA, Yoo SS. Focused ultrasound-mediated suppression of chemically-induced acute epileptic EEG activity. BMC Neurosci. 2011 Mar 6;12:23.
120. Craske MG, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**, Rose RD, Lang AJ, Welch S, Campbell-Sills L, Golinelli D, Roy-Byrne P. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry. 2011 Apr;68(4):378-88
121. Rapgay L, **Bystritsky A**, Dafter RE, Spearman M. New Strategies for Combining Mindfulness with Integrative Cognitive Behavioral Therapy for the Treatment of Generalized Anxiety Disorder. J Ration Emot Cogn Behav Ther. 2011 Jun;29(2):92-119. Epub 2009 Jun 10.
122. Rose RD, Lang AJ, Welch SS, Campbell-Sills L, Chavira DA, Sullivan G, Sherbourne C, **Bystritsky A**, Stein MB, Roy-Byrne PP, Craske MG. Training primary care staff to deliver a computer-assisted cognitive-behavioral therapy program for anxiety disorders. Gen Hosp Psychiatry. 2011 Jul-Aug;33(4):336-42. Epub 2011 Jun 8.
123. **Bystritsky A**, Korb AS, Douglas PK, Cohen MS, Melega WP, Mulgaonkar AP,

DeSalles A, Min BK, Yoo SS. A review of low-intensity focused ultrasound pulsation. *Brain Stimul.* 2011 Jul;4(3):125-36. Epub 2011 Apr 1.

124. Shiovitz TM, Zarrow ME, Shiovitz AM, **Bystritsky A**. Failure rate and "professional subjects" in clinical trials of major depressive disorder. *J Clin Psychiatry.* 2011 Sep;72(9):1284.
125. Mulgaonkar AP, Singh RS, Babakhanian M, Culjat MO, Grundfest WS, Gorgulho A, Lacan G, De Salles AA, **Bystritsky A**, Melega WP. A prototype stimulator system for noninvasive low intensity focused ultrasound delivery. *Stud Health Technol Inform.* 2012;173:297-303.
126. **Bystritsky A**, Nierenberg AA, Feusner JD, Rabinovich M. Computational non-linear dynamical psychiatry: a new methodological paradigm for diagnosis and course of illness. *J Psychiatr Res.* 2012 Apr;46(4):428-35. Epub 2012 Jan 18. Review.
127. **Bystritsky A**, Hovav S, Sherbourne C, Stein MB, Rose RD, Campbell-Sills L, Golinelli D, Sullivan G, Craske MG, Roy-Byrne PP. Use of complementary and alternative medicine in a large sample of anxiety patients. *Psychosomatics.* 2012 May;53(3):266-72. Epub 2012 Feb 1.
128. Feusner JD, Madsen S, Moody TD, Bohon C, Hembacher E, Bookheimer SY, **Bystritsky A**. Effects of cranial electrotherapy stimulation on resting state brain activity. *Brain Behav.* 2012 May;2(3):211-20.
129. Lang AJ, Wilkins K, Roy-Byrne PP, Golinelli D, Chavira D, Sherbourne C, Rose RD, **Bystritsky A**, Sullivan G, Craske MG, Stein MB. Abbreviated PTSD Checklist (PCL) as a guide to clinical response. *Gen Hosp Psychiatry.* 2012 Jul-Aug;34(4):332-8. Epub 2012 Mar 27.
130. Sullivan G, Sherbourne C, Chavira DA, Craske MG, Gollineli D, Han X, Rose RD, **Bystritsky A**, Stein MB, Roy-Byrne P, Stein MB, Roy-Byrne P. Does a quality improvement intervention for anxiety result in differential outcomes for lower income patients?. *Am J Psychiatry.* 2013 Feb;170(2):218-25. doi: 10.1176/appi.ajp.2012.12030375
131. Niles AN, Sherbourne CD, Roy-Byrne PP, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. Anxiety treatment improves physical functioning with oblique scoring of the SF-12 Short Form Health Survey. *Gen Hosp Psychiatry.* 2013 Jan 16. doi: 10.1016/j.genhosppsy.2012.12.004.
132. Campbell-Sills L, Sherbourne CD, Roy-Byrne P, Craske MG, Sullivan G, **Bystritsky A**, Lang AJ, Chavira DA, Rose RD, Shaw Welch S, Stein MB. Effects of co-occurring depression on treatment for anxiety disorders: analysis of outcomes from a large primary care effectiveness trial. *J Clin Psychiatry.* 2012 Dec;73(12):1509-16. doi: 10.4088/JCP
133. Brown LA, Craske MG, Glenn DE, Stein MB, Sullivan G, Sherbourne C, **Bystritsky A**, Welch SS, Campbell-Sills L, Lang A, Roy-Byrne P, Rose RD. CBT competence in novice therapists improves anxiety outcomes. *Depress Anxiety.* 2013 Feb;30(2):97-115. doi: 10.1002/da.22027.

134. **Bystritsky A**, Khalsa SS, Cameron ME, Schiffman J. Current diagnosis and treatment of anxiety disorders. *Journal of Clinical Pharmacy and Therapeutics*, 2013 Jan;38(1):30-57.
135. Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, **Bystritsky A**, Roy-Byrne P, Stein MB. Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. *Psychiatry Res*. 2015 Sep 30;229(1-2):133-42.
136. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, **Bystritsky A**, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry*. 2015 Feb;14(1):64-73.
137. Wolitzky-Taylor K, Brown LA, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care. *J Anxiety Disord*. 2015 Mar;30:88-93
138. **Bystritsky A**, Kronemyer D. Stress and anxiety: counterpart elements of the stress/anxiety complex. *Psychiatr Clin North Am*. 2014 Dec;37(4):489-518
139. Brown LA, Krull JL, Roy-Byrne P, Sherbourne CD, Stein MB, Sullivan G, Rose RD, **Bystritsky A**, Craske MG. An examination of the bidirectional relationship between functioning and symptom levels in patients with anxiety disorders in the CALM study. *Psychol Med*. 2015 Feb;45(3):647-61.
140. Kronemyer D, **Bystritsky A**. A non-linear dynamical approach to belief revision in cognitive behavioral therapy. *Front Comput Neurosci*. 2014 May 15;8:55.
141. Chavira DA, Golinelli D, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Rose RD, Lang AJ, Campbell-Sills L, Welch S, Bumgardner K, Glenn D, Barrios V, Roy-Byrne P, Craske M. Treatment engagement and response to CBT among Latinos with anxiety disorders in primary care. *J Consult Clin Psychol*. 2014 Jun;82(3):392-403.
142. Brown LA, Wiley JF, Wolitzky-Taylor K, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, Rose RD, **Bystritsky A**, Craske MG. Changes in self-efficacy and outcome expectancy as predictors of anxiety outcomes from the CALM study. *Depress Anxiety*. 2014 Aug;31(8):678-89.
143. **Bystritsky A**, Danial J, Kronemyer D. Interactions between diabetes and anxiety

- and depression: implications for treatment. *Endocrinol Metab Clin North Am.* 2014 Mar;43(1):269-83.
144. Khalsa SS, Shahabi L, Ajjola OA, **Bystritsky A**, Naliboff BD, Shivkumar K. Synergistic application of cardiac sympathetic decentralization and comprehensive psychiatric treatment in the management of anxiety and electrical storm. *Front Integr Neurosci.* 2014 Jan 2;7:98.
145. Dour HJ, Wiley JF, Roy-Byrne P, Stein MB, Sullivan G, Sherbourne CD, **Bystritsky A**, Rose RD, Craske MG. Perceived social support mediates anxiety and depressive symptom changes following primary care intervention. *Depress Anxiety.* 2014 May;31(5):436-42. doi: 10.1002/da.22216. Epub 2013 Dec 12. PubMed PMID: 24338947; PubMed Central PMCID: PMC4136523.
146. **Bystritsky A**, Korb A.S. A Review of Low Intensity Transcranial Focused Ultrasound for Clinical Applications. *Curr Behav Neurosci Rep* (2015) 2:60–66
147. Wolitzky-Taylor K, Brown LA, Roy-Byrne P, Sherbourne C, Stein MB, Sullivan G, **Bystritsky A**, Craske MG. The impact of alcohol use severity on anxiety treatment outcomes in a large effectiveness trial in primary care. *J Anxiety Disord.* 2015 Mar;30:88-93.
148. Bystritsky A, Kronemyer D. Stress and anxiety: counterpart elements of the stress/anxiety complex. *Psychiatr Clin North Am.* 2014 Dec;37(4):489-518.
149. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, **Bystritsky A**, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. *World Psychiatry.* 2015 Feb;14(1):64-73.
150. Bomyea J, Lang A, Craske MG, Chavira DA, Sherbourne CD, Rose RD, Golinelli D, Campbell-Sills L, Welch SS, Sullivan G, Bystritsky A, Roy-Byrne P, Stein MB. Course of symptom change during anxiety treatment: Reductions in anxiety and depression in patients completing the Coordinated Anxiety Learning and Management program. *Psychiatry Res.* 2015 Sep 30;229(1-2):133-42
151. Monti MM, Schnakers C, Korb AS, Bystritsky A, Vespa PM. Non-Invasive Ultrasonic Thalamic Stimulation in Disorders of Consciousness after Severe Brain Injury: A First-in-Man Report. *Brain Stimul.* 2016 Nov - Dec;9(6):940-941
152. Campbell-Sills L, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Stein MB. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. *Depress Anxiety.* 2016

Dec;33(12):1099-1106.

- 153.** Niles AN, Loerinc AG, Krull JL, Roy-Byrne P, Sullivan G, Sherbourne CD, Bystritsky A, Craske MG. Advancing Personalized Medicine: Application of a Novel Statistical Method to Identify Treatment Moderators in the Coordinated Anxiety Learning and Management Study. *Behav Ther.* 2017 Jul;48(4):490-500.
- 154.** Petkus AJ, Wetherell JL, Stein MB, Chavira DA, Craske MG, Sherbourne C, Sullivan G, Bystritsky A, Roy-Byrne P. Age Differences in Death and Suicidal Ideation in Anxious Primary Care Patients. *Clin Gerontol.* 2017 Jul 25:1-11.

20 other papers were submitted or published since 2017

RESEARCH PAPERS (non-peer reviewed)

1. **Bystritsky A.** Imipramine in panic/agoraphobia: Finding the dose, Clinical Psychiatry News, 22:5:2 & 21, 1994.
2. **Bystritsky A.** Pharmacological treatment of social phobia, Newsletter, Southern California Psychiatric Association, 1996.
3. Feusner J, **Bystritsky A.** Management of Treatment Resistant OCD, Psychiatric Times, XXII (8):18-22, 2005.

BOOKS/BOOK CHAPTERS

1. **Bystritsky A**, Martynichkin AV. The study of the tranquilizing action of lorazepam and chlordiazepoxide on the models of concurrent interaction, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
2. Katkova EB, **Bystritsky AS**, Martynichkin AV. The comparative effect of sidnocarbe and amphetamine on the emotional behavior act, In: Valdman AV (Ed.). Psychopharmacology of Emotional Stress and Zoosocial Interactions, Medical Literature, Leningrad, 1975.
3. Goldstein M, Lew JY, **Bystritsky A**, Liberman A, Engel J, Lilijequist S. Multiple dopamine receptors: Interaction with alpha-2 receptors, In: Agnoli A, Crepaldi G, Spano PF, Trabucchi M (Eds.). Aging Brain and Ergot Alkaloids, 241-248. Raven Press, New York, 1983.
4. Pasnau RO, **Bystritsky A.** The anxiety disorders: A review, In: Kales A, Pierce C, Greenblatt M (Eds.). The Mosaic of Contemporary Psychiatry in Perspective, 1992.
5. Pasnau RO, **Bystritsky A.** Anxiety and depression, coexistence and comorbidity, In: Den Boer I (Ed.). Handbook of Anxiety and Depression, Elsevier, 1995.
6. **Bystritsky A**, Williams K., Treatment of Panic Disorder, In: Rakel and Bope (Eds.), Conn's Current Therapy Guide, Elsevier, 2005, 2006, 2007 editions.
7. **Bystritsky A.** Neuropharmacological and Therapeutic Aspects of Panic Disorders, St. Petersburg, 2006.
8. Rapgay L, **Bystritsky A.** Longevity & Optimal Health: Integrating Eastern and Western Perspectives. February 2008, edited by W. C. Bushell, MIT; & Eium L Olivo, Columbia University.
9. **Bystritsky A.** ABC of Anxiety, Self-Help Brochure, 2010
10. **Bystritsky A.** UP-TO-DATE section on GAD, Social Anxiety, Pharmacological Treatment of Anxiety and Alternative and Herbal Treatments of Anxiety.

LETTERS TO THE EDITOR

1. **Bystritsky A.** A case report of high dose klonopin dependence, Clinical Psychiatry, 1993.
2. **Bystritsky A, Vapnik T.** Dymorphobia group treatment, Letter, Peer Reviewed, Depress Anxiety, 5:39-40, 1997.

ABSTRACTS

1. Petriaevskaya NV, Nesterovich NA, Martynichkin AV, **Bystritsky A.** The Pharmacological regulation of acute and chronic stress in an experiment, In: Theses of the 4th All-Union Congress of Pharmacology, Leningrad, 1976.
2. **Bystritsky A, Ware JE, Linn LS.** Development of a four dimensional anxiety scale, Abstracts of National Meeting of R.W.J. Clinical Scholars, Tampa, FL, 1988.
3. Shekim WO, **Bystritsky A, Hess EB.** Anxiety disorders and ADHD, New Research Abstracts, American Psychiatric Association, NR328, 1989.
4. Levine S, **Bystritsky A.** The treatment of major depression, new onset, in patients with HIV Positive serology, without active disease, with fluoxetine, Abstract C.584, Fifth International Conference on AIDS, International Development Research Center, page 655, 1989.
5. Levine SH, Anderson D, **Bystritsky A.** The treatment and evaluation of depression in patients infected with HIV, Abstract 54, presented at APA, paper session (peer reviewed), 87-88, New York, 1990.
6. **Bystritsky A, Fogelson DL, Doctor R.** Differences between patients with different orientation, Abstract 98, Presented at APA, paper session (peer reviewed), 103, New York, 1990.

7. Targ E, Karasic D, **Bystritsky A**, Diefenbach P, Anderson D, Fawzy F. Structured group therapy and fluoxetine as treatment for mood disorder in HIV-seropositive individuals, Abstract, International Conference on AIDS, Amsterdam, 1992.
8. Fredrick N, Martin K, Baxter L, **Bystritsky A**. A day hospital program for OCD, Abstract, Anxiety Disorders Association Conference, Charleston, SC, 1993.
9. **Bystritsky A**, Rosen RM, Faull K, Murphy KJ. Double-blind pilot trial of desipramine vs. fluoxetine in panic patients, Abstract, ADAA Meeting, Santa Monica, 1994.
10. Gorbis E, Munford PR, **Bystritsky A**. Abuse as a factor in expression and treatment of OCD, Abstract, ADAA Meeting, Santa Monica, 1994.
11. Lipovetsky V, **Bystritsky A**. Prevalence of anxiety disorders in a sample of immigrants from Russia, Abstract, ADAA Meeting, Santa Monica, 1994.
12. **Bystritsky A**, Craske MG, Shapiro D. Ambulatory blood pressure monitoring in panic patients, Abstract, ADAA Meeting, Santa Monica, 1994.
13. Vapnik T, Martin K, **Bystritsky A**. OCD and the family perspective, Abstract, ADAA Meeting, Santa Monica, 1994.
14. Small G, Schneider LS, Holman S, **Bystritsky A**. Site variability in a geriatric depression trial, Abstract, APA Meeting, Philadelphia, 1994.
15. Small G, Schneider LS, Holman S, **Bystritsky A**. Estrogen plus fluoxetine for geriatric depression, Abstract, APA Meeting, Philadelphia, 1994.
16. Craske MG, Maidenberg E, **Bystritsky A**. Brief cognitive behavior treatment of panic, Abstract, Symposium at AABT, Treatment of Panic with Agoraphobia. San Diego, 1994.
17. Kronig MH, Apter J, Asnis G, **Bystritsky A**, et al. A multicenter trial of sertraline for obsessive compulsive disorder, Abstract, American College of Neuropsychopharmacology, San Juan, 1995.
18. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during CO₂ presentation, inhalation procedure, Abstract and Poster Annual Meeting, American Psychiatric Association, New York, 1996.
19. **Bystritsky A**, Maidenberg E, Craske MG, Vapnik T, Schapiro D. Autonomic reactivity of panic patients during psychophysiological assessment. Abstract and Oral presentation, Symposium on Psychophysiology of Panic Disorder, Abstract, Annual Meeting, American Psychiatric Association, San Diego, 1997.

20. **Bystritsky A**, Vapnik T, Leuchter A. Computerized EEG Abnormalities in non-medicated panic patients, Abstract and Poster, presented at NCDEU Meeting Boca Raton, FL, 1997.
21. **Bystritsky A**, Saxena S, Maidment K, Vapnik T, Tarlow G, Rosen R. Quality of life changes in treatment-resistant OCD, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
22. **Bystritsky A**, Rosen R, Suri R, Vapnik T. Pilot open-label study of nefazodone in panic disorder, Abstract and Poster presentation, ACNP Meeting, Waikoloa Village, HI, 1997.
23. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Breathing configuration of panic patients during a CO₂ inhalation procedure, Abstract and Poster presented at NCDEU Meeting, Boca Raton, FL, 1998.
24. **Bystritsky A**, Liberman RP, Hwang S, Saxena S, Maindment K, Vapnik T. Comparison of the functional status of patients with severe obsessive-compulsive disorder vs. schizophrenia pre-and post-treatment, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
25. Ackerman DL, Greenland S, **Bystritsky A**, Small G. Side effects and time of response in placebo-controlled trial of fluoxetine in geriatric depression, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
26. Ackerman DL, **Bystritsky A**. Utilization and cost comparison of inpatient antidepressant drugs, Abstract, NCDEU Meeting, Boca Raton, FL, 1999.
27. **Bystritsky A**, Maindment K, Vapnik T, Tarlow G. Management clients with treatment resistant OCD, Abstract and Symposium presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
28. **Bystritsky A**, Craske MG, Maidenberg E, Vapnik T, Schapiro D. Cardiovascular and respiratory changes in panic patients in the light of current biological theories of Panic, Abstract and Oral Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
29. **Bystritsky A**, Craske MG, Sandbrand DC. Preliminary analysis of the neuropsychological effects of visual imagery in panic disorder patients: An fMRI study, Abstract and Oral Presentation, presented at the Anxiety Disorders Association of America Annual Meeting, San Diego, 1999.
30. **Bystritsky A**, Bystritsky M. Russian language assessment of mental illness, Symposium Presentation and Abstract, Annual Meeting of American Psychiatric Association, Washington DC, 1999.

31. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract and Poster, ACNP, San Juan, 2000.
32. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure, Abstract and Poster, ACNP, San Juan, 2000.
33. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract, Eli Lilly Investigators Conference, Dallas, 2001.
34. **Bystritsky A**, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S. Augmentation of SRI response in refractory OCD using adjunct olanzapine: A placebo-controlled study, Abstract, New Clinical Drug Evaluation Unit Program, Boca Raton, FL, 2001.
35. **Bystritsky A**, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. FMRI changes in panic patients during imagery exposure. Presentation and Abstract, Psychiatric Research Society, Park City, UT, 2001.
36. Roy-Byrne P, Russo J, Pollack M, Steward R, **Bystritsky A**, Bell J, Rosenbaum J, Corrigan MH, Stolk J, Rush AJ, Ballenger J. Personality and symptom sensitivity predictors of alprazolam withdrawal in panic disorder, Abstract and Poster, ACNP, San Juan, 2002.
37. Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB, Katon WJ, Sullivan G, Means A, **Bystritsky A**. CBT and Medication for Primary Care Panic Disorder: Sustained Superiority to Usual Care, Abstract and Poster, ACNP, San Juan, 2002.
38. **Bystritsky, A**. Current Treatments of OCD. Abstract and Poster Proceeding of the Bekhterev Institute, St. Petersburg, Russia, July 2002.
39. **Bystritsky, A**. OCD Management in Partial Program, Abstract and Poster, 6th IOCDC Meeting, Lanzarote, Spain, November 2003.
40. **Bystritsky, A**. Anxiety as Residual Symptoms of Depression, APA Symposia and Abstract., APA Annual Meeting, New York, May 2004.
41. Feusner, JD, **Bystritsky A**. Effect Size of UCLA 4-D Anxiety-Depression Scale as Compared to Other Anxiety Scales, Abstract and Poster, Anxiety Disorder Association Of America, Abstract and Poster, Florida, March 2004.
42. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, 1-67. New Clinical Drug Evaluation Unit Program, Boca Raton, FL, May 2005.

43. **Bystritsky A**, Natoli J, Klap R, Wells KB, Young A. Prevalence of Psychiatric Comorbidities Among Subjects with Clinical and Subthreshold Panic Disorder. Abstract and Poster, International Conference: Bridging Eastern and Western Psychiatry, Moscow, June 2005.
44. Prenoveau JM, Craske M, Roy-Byrne PP, Sherbourne CD, Stein MB, **Bystritsky A**. Predictors of Willingness to Consider Medication and Psychological Treatment for Panic Disorder in Primary Care. Abstract and Poster, Association of Behavior and Cognitive Therapies. Washington D.C., November, 2005.
45. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, Psychiatric Congress, Las Vegas, November, 2005.
46. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, ACNP, Hawaii, December, 2005.
47. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, APA, Toronto, May, 2006.
48. **Bystritsky A**, Koback K., Vapnik T. A Double Blind, Placebo Controlled Trial of St. John's Wart in OCD, Paper and Abstract, Complimentary and Alternative Treatments Conference, Edmonton-Alberta, Canada, May 2006.
49. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, NCDEU, Boca Raton, Florida, June, 2006.
50. **Bystritsky A**, Kerwin L, Vapnik T. A Pilot Controlled Trial of Bupropion vs.Es-Citalopram in GAD, Abstract and Poster, Institute of Psychiatry, New York, October, 2006.
51. Feusner JD, **Bystritsky A**, Townsend J, Bookheimer S. Visual information processing of faces in body dysmorphic disorder. Abstract and Poster, The American College of Neuropsychopharmacology Annual Meeting, 2006.
52. Powers MB, Smits J, Whitley D, **Bystritsky A**, Telch M. Attributional processes concerning medication taking following exposure-based treatment and their subsequent effects on return of fear at follow-up. Anxiety Disorders Association of America, St. Louis, Missouri. Abstract, March, 2007.
53. **Bystritsky A**, Kerwin L, Feusner JD. A pilot study of *Rhodiola rosea* (Rhodax®) for generalized anxiety disorder (GAD). Abstract, American Psychiatric Association annual meeting, 2007.
54. Feusner JD, Townsend J, **Bystritsky A**, McKinley M, Bookheimer S. Magnetic resonance volumetric analysis of brain regions in body dysmorphic disorder: preliminary results. Abstract, American College of Neuropsychopharmacology Annual Meeting, Boca Raton, FL, 2007.

55. **Bystritsky A**, Kaplan J, Feusner JD, Wadekar M, Burock M, Iacoboni M. A preliminary study of fMRI-guided rTMS in the treatment of Generalized Anxiety Disorder . Abstract, American College of Neuropsychopharmacology Annual Meeting, Boca Raton, FL, 2007.
56. Powers MB, Smits J, Whitley D, **Bystritsky A**, Telch M. Attribution processes concerning medication taking following exposure-based treatment and their subsequent effects on return of fear at follow-up. Abstract and Presentation, World Congress of Behavioural and Cognitive Therapies, Barcelona, Spain, July, 2007.
57. Powers MB, Smits JA, Whitley D, **Bystritsky A**, Telch M. Attributional processes concerning medication taking and their subsequent effects on fear reduction during exposure-based treatment: A work in progress. Poster and Abstract, the Association for the Advancement of Behavior Therapy, New Orleans, Louisiana, 2007.
58. Feusner JD, Townsend J, **Bystritsky A**, McKinley M, Moller H, Bookheimer S. Magnetic resonance volumetric analysis of brain regions in body dysmorphic disorder. Poster presented at the Organization for Human Brain Mapping Annual Conference, Melbourne, Australia, 2008
59. Feusner JD, Kerwin L, Saxena S, **Bystritsky A**. Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open Label Trial. Poster presented at the 15th Annual Obsessive-Compulsive Foundation Conference, Boston, MA, 2008
60. **Bystritsky A**, Hembacher, E, Moody T, Hoffman J, Feusner JD. Effects of cranial electrotherapy stimulation on brain activity. Poster presented at the American College of Neuropsychopharmacology 2009 48th Annual Meeting, Dec. 8th, 2009
61. Feusner JD, Moody T, Hembacher E, Hoffman J, Bookheimer S, **Bystritsky A**. Effects of cranial electrotherapy stimulation on resting brain activity. Poster presented at the 2010 Organization for Human Brain Mapping Annual Conference, Barcelona, Spain
62. Feusner JD, Moody T, Hembacher E, Hoffman J, Bookheimer S, **Bystritsky A**. Effects of cranial electrotherapy stimulation on resting brain activity. Poster presented at the 2010 NCDEU Annual Meeting
63. Kerwin L, Moller H, **Bystritsky A**, Feusner JD. Global-Local Visual Processing in Body Dysmorphic Disorder. Poster presented at the 2010 International Obsessive Compulsive Foundation Conference
64. Yoo SS, Lee JH, Fischer K, Zhang Y, **Bystritsky A**, McDannold N, Jolesz FA. (2008) FUS-mediated reversible modulation of region-specific brain function. Proceedings of MRgFUS, p. 10.
65. Yoo SS, Lee JH, Fischer K, Zhang Y, **Bystritsky A**, McDannold N, Jolesz FA. (2009) Non-invasive regional modulation of brain function by focused ultrasound. Proceedings of Society for Neuroscience, p. 105.111.

Over 20 other invited or honorary lectures or abstracts in recent years

MANUALS/SCALES

1. **Bystritsky A**, Ware JE, Linn LS. Four Dimensional Anxiety Scale (FDAS) Manual, University of California, Los Angeles, 1988.
2. **Bystritsky A**, Selivra E, Bystirsky M. M.I.N.I Diagnostic Interview, Russian Translation, 1998, 2004.
3. Craske MG, Roy-Byrne PP, Stein MB, **Bystritsky A**. Collaborative Care Manual For Treatment of Panic In Primary Care, 2000, 2004.
4. **Bystritsky A.**, ABC of Anxiety, Treatment Manual and Brochure, Jan 2010

Patents:

Patent “Method of Modifying Electrical Currents in Neuronal Circuits”, USPTO 7,283,861 - 2002

Continuation in Part for the same, USPTO 8,086,296 -- 2007

Continuation in Part for the application, 12/707,197 – 2009

Several more patents are either pending or issued for Brainsonix Corporation